ANAB AnaptysBio Inc.

+2.11  (+3%)
Previous Close 68.55
Open 69.09
Price To Book 4.08
Market Cap 1909496409
Shares 27,023,725
Volume 384,222
Short Ratio
Av. Daily Volume 254,855

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2H 2019.
ANB020 - etokimab
Moderate-to-severe adult atopic dermatitis
Phase 2a data to be presented at EAACI Congress June 5, 2019.
ANB020 - etokimab
Severe adult eosinophilic asthma
Phase 2 data due 1H 2020.
Palmo-plantar pustular psoriasis
Phase 2 data due mid-2019.
Generalized pustular psoriasis
Phase 2 data due 2H 2019.
ANB020 - etokimab
Nasal polyps

Latest News

  1. AnaptysBio Started 2019 Quiet as a Ninja
  2. AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
  3. Is AnaptysBio, Inc. (ANAB) A Good Stock To Buy?
  4. AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference
  5. What Makes AnaptysBio, Inc. (ANAB) a New Strong Buy Stock
  6. Will AnaptysBio Continue to Surge Higher?
  7. Introducing AnaptysBio (NASDAQ:ANAB), The Stock That Dropped 42% In The Last Year
  8. All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy
  9. AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
  10. AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
  11. AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference
  12. Hedge Funds Are Crazy About AnaptysBio, Inc. (ANAB)
  13. Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  14. Here's Why AnaptysBio, Inc. Slipped on Friday
  15. AnaptysBio Inc. Sets Up More Shots on Goal in the Third Quarter
  16. AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates
  17. AnaptysBio to Participate in Upcoming Investor Conferences
  18. Here's Why AnaptysBio Rose 12.6% in September